The expression and role of Fas ligand in intestinal inflammation

Neurogastroenterology and Motility

Volumn 16, Issue 1, 2004, Pages 61-74

  Sayani, F A ^a   Keenan, C M ^a,b   Van Sickle, M D ^a,b   Amundson, K R ^a,b   Parr, E J ^a,b   Mathison, R D ^a   Macnaughton, W K ^b   Braun, J E A ^b   Sharkey, K A ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Enteric nervous system; Myenteric plexus; Neutrophils; Submucosal plexus; T cells

Indexed keywords

FAS LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; ENTERITIS; GANGLION; GUINEA PIG; ILEITIS; IMMUNOREACTIVITY; INTESTINE INNERVATION; INTESTINE MOTILITY; INTESTINE SECRETION; MALE; MOUSE; MOUSE STRAIN; NERVE CELL; NERVE FIBER; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; COLITIS; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; GASTROINTESTINAL TRANSIT; GUINEA PIGS; ILEITIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MYENTERIC PLEXUS; NEUTROPHILS; TRINITROBENZENESULFONIC ACID;

EID: 1342288976     PISSN: 13501925     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2982.2003.00457.x     Document Type: Article

References (49)

1. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-95.
2. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33: 29-55.
3. Pinkoski MJ, Green DR. Fas ligand, death gene. Cell Death Differ 1999; 6: 1174-81.
4. Sharma K, Wang RX, Zhang LY et al. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 2000; 88: 333-47.
5. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
6. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16: 39-43.
7. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9: 243-69.
8. Pinkoski MJ, Brunner T, Green DR, Lin T. Fas and Fas ligand in gut and liver. Am J Physiol Gastrointest Liver Physiol 2000; 278: G354-66.
9. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-2.
10. French LE, Hahne M, Viard I et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 335-43.
11. Mitsiades N, Poulaki V, Mitsiades CS, Koutras DA, Chrousos GP. Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. Trends Endocrinol Metab 2001; 12: 384-90.
12. Parr EJ, Myles EB, Hanani M, Seror D, Riabowol KT, Sharkey KA. Immunoreactivity for the Fas ligand in the mammalian enteric nervous system. Cell Tissue Res 1997; 290: 21-29.
13. Geboes K, Collins S. Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol Motil 1998; 10: 189-202.
14. Sharkey KA, Kroese AB. Consequences of intestinal inflammation on the enteric nervous system: neuronal activation induced by inflammatory mediators. Anat Rec 2001; 262: 79-90.
15. Lynch DH, Watson ML, Alderson MR et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994; 1: 131-6.
16. Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-76.
17. McCafferty DM, Miampamba M, Sihota E, Sharkey KA, Kubes P. Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice. Gut 1999; 45: 864-73.
18. Miller MJS, Sadowska-Krowicka H, Jeng AY et al. Substance P levels in experimental ileitis in guinea-pigs: Effects of misoprostol. Am J Physiol Gastrointest Liver Physiol 1993; 265: G321-30.
19. McCafferty D-M, Sharkey KA, Wallace JL. Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol Gastrointest Liver Physiol 1994; 266: G560-7.
20. Parr EJ, Sharkey KA. The use of constitutive nuclear oncoproteins to count neurons in the enteric nervous system of the guinea-pig. Cell Tissue Res 1994; 277: 325-31.
21. Sainio-Pollanen S, Erkkila S, Alanko S, Hanninen A, Pollanen P, Simell O. The role of Fas ligand in the development of insulitis in nonobese diabetic mice. Pancreas 1998; 16: 154-9.
22. Sugihara A, Saiki S, Tsuji M et al. Expression of Fas and Fas ligand in the testes and testicular germ cell tumors: an immunohistochemical study. Anticancer Res 1997; 17: 3861-5.
23. Morimoto Y, Morimoto H, Okamura H et al. Upregulation of the expression of Fas antigen and Fas ligand in a human submandibular gland ductal cell line by okadaic acid. Arch Oral Biol 2000; 45: 657-66.
24. Strater J, Walczak H, Hasel C, Melzner I, Leithauser F, Moller P. CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies. Cell Death Differ 2001; 88: 273-8.
25. Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia 1999; 27: 62-74.
26. Medana I, Li Z, Flugel A, Tschopp J, Wekerle H, Neumann H. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity. J Immunol 2001; 167: 674-81.
27. Bush TG, Savidge TC, Freeman TC et al. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 1998; 93: 189-201.
28. Gershon MD, Rothman TP. Enteric glia. Glia 1991; 4: 195-204.
29. Shin DH, Lee E, Kim HJ et al. Fas ligand mRNA expression in the mouse central nervous system. J Neuroimmunol 2002; 123: 50-57.
30. Moalem G, Monsonego A, Shani Y, Cohen IR, Schwartz M. Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J 1999; 13: 1207-17.
31. Choi C, Park JY, Lee J et al. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma. J Immunol 1999; 162: 1889-95.
32. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999; 20: 46-52.
33. Bradley JS Jr, Parr EJ, Sharkey KA. Effects of inflammation on cell proliferation in the myenteric plexus of the guinea-pig ileum. Cell Tissue Res 1997; 289: 455-61.
34. Geboes K, Rutgeerts P, Ectors N et al. Major histocompatibility class II expression on the small intestinal nervous system in Crohn's disease. Gastroenterology 1992; 103: 439-47.
35. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 1995; 14: 1129-35.
36. Sanovic S, Lamb DP, Blennerhassett MG. Damage to the enteric nervous system in experimental colitis. Am J Pathol 1999; 155: 1051-7.
37. Yukawa M, Iizuka M, Horie Y et al. Systemic and local evidence of increased Fas-mediated apoptosis in ulcerative colitis. Int J Colorectal Dis 2002; 17: 70-76.
38. Ueyama H, Kiyohara T, Sawada N et al. High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. Gut 1998; 43: 48-55.
39. Strater J, Wellisch I, Riedl S et al. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 1997; 113: 160-7.
40. Iwamoto M, Koji T, Makiyama K, Kobayashi N, Nakane PK. Apoptosis of crypt epithelial cells in ulcerative colitis. J Pathol 1996; 180: 152-9.
41. Coffey JC, Bennett MW, Wang JH et al. Upregulation of Fas-Fas-L (CD95/CD95L)-mediated epithelial apoptosis-a putative role in pouchitis? J Surg Res 2001; 98: 27-32.
42. Simpson SJ, De Jong YP, Shah SA et al. Consequences of Fas-ligand and perforin expression by colon T cells in a mouse model of inflammatory bowel disease. Gastroenterology 1998; 115: 849-55.
43. Beck PL, Wong J, Muruve D. The regulation of Fas and Fas ligand alters the severity of murine model of colitis. Gastroenterology 2002; 122: A269-70.
44. Osborne BA. Apoptosis and the maintenance of homoeostasis in the immune system. Curr Opin Immunol 1996; 8: 245-54.
45. Rathmell JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 2002; 109(Suppl): S97-107.
46. Bonfoco E, Stuart PM, Brunner T et al. Inducible non-lymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 1998; 9: 711-20.
47. Hahne M, Peitsch MC, Irmler M et al. Characterization of the non-functional Fas ligand of gld mice. Int Immunol 1995; 7: 1381-6.
48. Chu JL, Ramos P, Rosendorff A et al. Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome. J Exp Med 1995; 181: 393-8.
49. Watanabe D, Suda T, Hashimoto H, Nagata S. Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. EMBO J 1995; 14: 12-18.